Skip to main content

Table 2 Changes in TILs and CD8+ T cells following NAC

From: Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

  Pre-NAC cohort (n = 6) Post-NAC cohort (n = 17)
Percentage of TILs
 Stromal TILs 29.8% (1–80%) 24.9% (2–70%)
Percentage of CD8+ T cells
 Overall CD8+ T cells 18.3% (0.5–60%) 15.7% (1–50%)
 Stromal CD8+ T cells 24.6% (1–70%) 21.2% (1–60%)
 Intratumoral CD8+ T cells 12.0% (0–50%) 7.9% (0–40%)
  1. Values are denoted as means with ranges in the parentheses